Genmab — Februar 2014
-
vi fik en fordobling af duo aftalen. de kan ikke lave mere. Vi har da også fået en del data. Jeg tror ikke vi kan forvente så meget mere. Genmab bliver ikke opkøbt lige nu og hvis så sker det med en meget stor præmie. Men jeg tror ikke det er tilfældet
-
man har da ihvertfald taget 10% ud af den ligning og det er rigtigt meget
-
10% af den samlede virksomheder på markedet ville have presset den højt op
-
det forstod I godt ikke?
-
jeg synes bare ikke det er en god ændring af strategi. ja jky vi venter noget om 10 minutter
-
131 for hele året. var det 125 de guidede?
-
GlaxoSmithKline plc and Genmab A/S (OMX: GEN) announced today that the US Food and Drug Administration (FDA) has granted Priority Review designation to the supplemental Biologics License Application (sBLA) for the use of Arzerra
(ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy. -
34 er godt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind